Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
All-access for blockbuster TB drug in South Africa

The country made history on Monday when the health department announced that all drug-resistant tuberculosis (DR-TB) patients will be eligible to receive the new medicine, bedaquiline. “The Department of Health’s [DoH] commitment on bedaquiline is momentous globally and marks a new era of DR-TB management where we are really prioritising the patient,” Doctors Without Borders’ Dr Anja Reuters told Health-e News.

Published
19 June 2018
From
Health-e
Transmitted drug resistance now less likely to harm HIV treatment options, US study finds

The rising prevalence of transmitted antiretroviral drug resistance in the United States is unlikely to affect the success of first-line treatment in the future and

Published
19 June 2018
By
Keith Alcorn
GSK's two-drug HIV treatment meets main goal in late stage studies

GlaxoSmithKline’s two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies, scoring key points in its rivalry with Gilead in the medical field. The combination of dolutegravir and lamivudine was shown to be as effective as a dolutegravir-based combination of three drugs, GSK’s majority-owned ViiV Healthcare said on Thursday.

Published
15 June 2018
From
Reuters
ART Simplification Does Not Affect Systemic Inflammation in Virologically Suppressed HIV

For virologically suppressed patients infected with HIV, switching to a dual antiretroviral maintenance therapy of atazanavir/ritonavir plus lamivudine does not affect plasma markers of systemic inflammation, according to results published in the Journal of Antimicrobial Chemotherapy.

Published
15 June 2018
From
Infectious Disease Advisor
'Emotional closeness’ key to successful HIV treatment support

The type of relationship someone living with HIV has with both their social network and a nominated ‘treatment partner’ is likely to influence whether they are virally suppressed, research from Botswana suggests.

Published
15 June 2018
From
AVERT
ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine

ViiV Healthcare today announced positive headline results from its phase III GEMINI study programme. The studies (GEMINI-1 and GEMINI-2) are designed to evaluate the safety and efficacy of a two-drug regimen (2DR) of dolutegravir and lamivudine compared to a three-drug regimen of dolutegravir and two nucleoside reverse transcriptase inhibitors, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), in treatment naïve HIV-1 infected adults with baseline viral loads less than 500,000 copies per ml.

Published
15 June 2018
From
ViiV Healthcare press release
Strategies for a cure

Three researchers talk with PA editor Jeff Berry about ongoing HIV cure research within the ACTG, treatment interruptions, and when we might see a cure.

Published
12 June 2018
From
Positively Aware
Russia’s HIV/AIDS epidemic is getting worse, not better

Almost anywhere in the world, an HIV-infected woman who has an uninfected partner and wants to have a baby would be first in line to receive ARVs. The challenges Katia faced in getting treatment amid Russia’s epidemic highlight the country’s faltering response, which critics have blasted as misguided, lackadaisical, and downright dismissive. Some federal health officials even question the term epidemic. “This is a very large and very serious epidemic, and certainly one of the few epidemics in the world that continues to get worse rather than get better,” says Vinay Saldanha, the Moscow-based regional director for the Joint United Nations Programme on HIV/AIDS (UNAIDS) in Eastern Europe and Central Asia. “This is a public health crisis.”

Published
12 June 2018
From
Science
Single Shot of PRO 140 mAb Cuts HIV Load in Two Thirds on Failing ART

PRO 140, a once-weekly subcutaneous monoclonal antibody (mAb), lowered viral loads by a half-log or more in two thirds of phase 2b/3 trial participants after an initial injection in combination with a failing antiretroviral regimen [1]. An extension study is testing longer-term response to PRO 140 in people using it with other antiretrovirals.

Published
11 June 2018
From
National AIDS Treatment Advocacy Project
Closer Monitoring Recommended for Older Patients Treated With Dolutegravir for HIV

The maximum concentration of the integrase inhibitor dolutegravir (DTG) was significantly higher in people living with HIV who are more than 60 years old compared with younger individuals, according to new findings published in Clinical Infectious Diseases.There have been recent concerns about DTG-related neuropsychiatric toxicity, especially among older patients with HIV.

Published
11 June 2018
From
Infectious Disease Advisor
← First12345...472Next →
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.